Tagraxofusp for Post-Transplant Maintenance
Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelofibrosis and Chronic Myelomonocytic Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 44 patients (estimated)
- Sponsors
- University of Virginia
- Tags
- CD123, Maintenance, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2125
- NCT Identifier
- NCT05233618
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.